Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors.

Mortazavi, Motahareh; Divar, Masoumeh; Damghani, Tahereh; Moosavi, Fatemeh; Saso, Luciano; Pirhadi, Somayeh; Khoshneviszadeh, Mehdi; Edraki, Najmeh; Firuzi, Omidreza

Mortazavi, Motahareh; Divar, Masoumeh; Damghani, Tahereh; Moosavi, Fatemeh; Saso, Luciano; Pirhadi, Somayeh; Khoshneviszadeh, Mehdi; Edraki, Najmeh; Firuzi, Omidreza.

Afiliación

Mortazavi M; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Divar M; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Damghani T; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Moosavi F; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Saso L; Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.
Pirhadi S; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Khoshneviszadeh M; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Edraki N; Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Firuzi O; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Front Chem ; 10: 969559, 2022.

Article en En | MEDLINE | ID: mdl-36465863

Palabras clave

anticancer agents; drug design; kinase inhibitors; multitargeted compounds; three-dimensional culture

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Chem Año: 2022 Tipo del documento: Article País de afiliación: Irán